These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11786175)

  • 41. A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation.
    Heslin M; Babalola O; Ibrahim F; Stringer D; Scott D; Patel A
    Value Health; 2018 Feb; 21(2):185-192. PubMed ID: 29477400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tutorial on health economics and outcomes research in nutrition.
    Philipson T; Linthicum MT; Snider JT
    JPEN J Parenter Enteral Nutr; 2014 Nov; 38(2 Suppl):5S-16S. PubMed ID: 25239114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systematic review and quality assessment of economic evaluation studies of injury prevention.
    Polinder S; Segui-Gomez M; Toet H; Belt E; Sethi D; Racioppi F; van Beeck EF
    Accid Anal Prev; 2012 Mar; 45():211-21. PubMed ID: 22269503
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Economic evaluation of interventions in public health: potentials and limitations].
    Le Gales C; Triomphe A
    Rev Epidemiol Sante Publique; 1991; 39 Suppl 1():S15-29. PubMed ID: 1908111
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures.
    Piette JD; Heisler M; Horne R; Caleb Alexander G
    Soc Sci Med; 2006 Feb; 62(4):846-57. PubMed ID: 16095789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Willingness to pay in the context of an economic evaluation of healthcare programs: theory and practice.
    Gafni A
    Am J Manag Care; 1997 May; 3 Suppl():S21-32. PubMed ID: 10180338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic evaluations of clinical pharmacy services: 2006-2010.
    Touchette DR; Doloresco F; Suda KJ; Perez A; Turner S; Jalundhwala Y; Tangonan MC; Hoffman JM
    Pharmacotherapy; 2014 Aug; 34(8):771-93. PubMed ID: 24644086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methodological assessment of economic evaluations of alcohol treatment: what is missing?
    Barbosa C; Godfrey C; Parrott S
    Alcohol Alcohol; 2010; 45(1):53-63. PubMed ID: 19808943
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Estimation and Inclusion of Presenteeism Costs in Applied Economic Evaluation: A Systematic Review.
    Kigozi J; Jowett S; Lewis M; Barton P; Coast J
    Value Health; 2017 Mar; 20(3):496-506. PubMed ID: 28292496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evidence from cost-effectiveness research.
    Noyes K; Holloway RG
    NeuroRx; 2004 Jul; 1(3):348-55. PubMed ID: 15717037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes measurement: health state preferences and economic evaluation.
    Oldridge NB
    Assist Technol; 1996; 8(2):94-102. PubMed ID: 10163933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Value for money in the health sector: the contribution of primary health care.
    Mills A; Drummond M
    Health Policy Plan; 1987 Jun; 2(2):107-28. PubMed ID: 10312103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic evaluation studies in nuclear medicine: a methodological review of the literature.
    Gambhir SS; Schwimmer J
    Q J Nucl Med; 2000 Jun; 44(2):121-37. PubMed ID: 10967623
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost and health care resource use associated with noncompliance with oral bisphosphonate therapy: an analysis using Danish health registries.
    Kjellberg J; Jorgensen AD; Vestergaard P; Ibsen R; Gerstoft F; Modi A
    Osteoporos Int; 2016 Dec; 27(12):3535-3541. PubMed ID: 27394414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations.
    Achilla E; McCrone P
    Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.